NASDAQ:ARDX - Ardelyx, Inc.
$2.42
 $-0.08
-3.20%
12:10PM EDT
2019-07-22
Ardelyx, Inc., incorporated on October 18, 2007, is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. The Company operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.Cardiorenal PortfolioAs of December 31, 2016, the Company's cardiorenal portfolio included two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. In addition to its two-phase III product candidates, the Company has two programs that are in research phase. Tenapanor is a minimally-systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduces sodium uptake from the gut. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ARDX     avg for
industry  
  avg for
sector  
42 stocks weight:  11. 62   217. 37   399. 45  
42 stocks rank:  3. 60 K 1. 27 K 716. 99  
# analyst opinions:  3. 00   13. 21   13. 71  
mean recommendation:  1. 20   2. 10   2. 04  

quick ratio:  7. 28   5. 49   1. 88  
current ratio:  7. 41   5. 87   2. 36  

target price low:  6. 00   83. 44   114. 90  
target price avg:  3. 71   106. 20   137. 90  
target price high:  15. 00   132. 30   158. 97  
1-yr high:  4. 45   111. 86   142. 57  
last close:  2. 50   86. 79   125. 44  
50-day avg:  2. 70   86. 68   122. 63  
200-day avg:  2. 83   89. 22   121. 38  
1-yr low:  1. 66   69. 78   100. 51  
volume:  60. 66 K 2. 62 M 3. 43 M
50-day avg volume:  125. 20 K 3. 20 M 4. 16 M
200-day avg volume:  230. 98 K 2. 99 M 4. 75 M

1-day return:  -2. 72 % -1. 30 % -0. 99 %
this week return:  -1. 57 % 0. 45 % -0. 20 %
12-wk return:  -27. 54 % 0. 94 % 4. 84 %
52-wk return:  -40. 23 % -1. 30 % 10. 55 %

enterprise value (EV):  60. 51 M 45. 10 B 122. 38 B
market cap:  156. 50 M 38. 96 B 108. 40 B
EBITDA:  -96. 08 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  -0. 63   5. 38   11. 93  
enterprise/revenue (EV/R):  210. 84   57. 92   10. 21  
total revenue:  287. 00 K 9. 91 B 39. 98 B
total debt:  55. 57 M 10. 90 B 17. 48 B
debt/equity:  60. 51   57. 18   120. 05  
net income (common):  -100. 42 M 2. 07 B 4. 05 B

shares outstanding:  62. 60 M 538. 09 M 1. 24 B
shares:  38. 68 M 548. 00 M 1. 22 B
shares short:  571. 01 K 10. 98 M 11. 87 M
shares short prior month:  587. 61 K 9. 32 M 12. 05 M
short ratio:  3. 47   5. 60   3. 34  
short % of float:  1. 22 % 6. 48 % 2. 64 %
total cash/share:  2. 42   10. 98   9. 19  
total cash:  151. 56 M 5. 93 B 6. 10 B
free cash flow:  -42. 41 M 2. 92 B 4. 55 B
operating cash flow:  -80. 38 M 3. 80 B 5. 78 B

book value:  1. 47   13. 35   27. 45  
price/book:  1. 70   4. 60   8. 78  
gross profits:  2. 14 M 7. 44 B 36. 13 B
operating margins:  -34411. 15 % -308. 40 % -28. 55 %
EBITDA margins:  0. 00 % 13. 17 % 23. 38 %
profit margins:  0. 00 % 10. 44 % 14. 18 %
gross margins:  99. 30 % 35. 80 % 55. 40 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 66 % 1. 03 %

1-yr EPS:  -1. 68   2. 10   4. 23  
forward EPS:  -1. 14   3. 45   7. 10  
P/E:  -1. 49   1. 90   32. 10  
forward P/E:  -2. 19   6. 46   15. 47  
PE/G:  0. 05   0. 70   -0. 54  
growth:  -29. 28 % 265. 63 % 79. 11 %
earnings high:  -0. 37   0. 89   1. 68  
earnings avg:  -0. 38   0. 70   1. 57  
earnings low:  -0. 40   0. 46   1. 46  
revenue high:  -0. 00   2. 57 B 11. 07 B
revenue avg:  -0. 00   2. 51 B 10. 91 B
revenue low:  -0. 00   2. 45 B 10. 73 B
return on assets:  -39. 96 % -2. 34 % 5. 28 %
return on equity:  -90. 96 % -90. 08 % 133. 53 %
revenue/share:  0. 01   12. 72   60. 04  

beta (1yr vs S&P500):  1. 75   1. 27   0. 91  
sharpe (1yr):  -0. 55   0. 16   0. 77  

held % insiders:  0. 98 % 6. 06 % 3. 29 %
held % institutions:  84. 81 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : ARDX
.    101.339 =       101.339 :: --> INITIAL WEIGHT <--
.    - 1.675 =        99.664 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 1.994 =       198.753 :: P/E factor
.    x 2.105 =       418.283 :: PE/G factor
.    x 1.644 =       687.592 :: beta factor
.    x 0.835 =       574.307 :: sharpe factor
.    x 2.737 =        1572.0 :: current ratio factor
.    x 1.077 =      1692.575 :: quick ratio factor
.    x 1.135 =      1921.042 :: short ratio factor
.    x 2.915 =      5599.407 :: EV/R factor
.    x 1.008 =      5646.916 :: price-to-book factor
.    x 0.638 =      3605.536 :: debt-to-revenue factor
.    x 1.394 =       5024.33 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =     10655.564 :: sector+industry 1-year gains factor
.    x 1.009 =     10756.025 :: industry 12-weeks return factor
.    x 1.308 =     14067.683 :: industry 2-weeks return factor
.    x 0.983 =     13831.493 :: "drift" penalty 5 days ago
.    / 2.003 =      6904.908 :: overall "drift" factor
.    x 0.905 =      6250.122 :: largest single-day jump factor
.    x 0.068 =       425.758 :: low price factor
.    x 0.566 =       240.787 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.    x 0.959 =       230.951 :: forward EPS factor
.    x 0.985 =       227.523 :: forward P/E factor
.    x 1.185 =       269.549 :: industry recommendation factor
.    x 2.776 =       748.389 :: company recommendation factor
.    x 1.003 =       750.458 :: factor historical industry gain for week 29
.   x 11.162 =      8376.522 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =         9.567 :: reduced for readability
.    + 2.056 =        11.622 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                     11.622 :: FINAL WEIGHT for NASDAQ:ARDX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org